5rek Citations

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.

Abstract

COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments were progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease.

Reviews - 5rek mentioned but not cited (1)

  1. Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to. Ojha PK, Kar S, Krishna JG, Roy K, Leszczynski J. Mol Divers 25 625-659 (2021)

Articles - 5rek mentioned but not cited (7)



Reviews citing this publication (43)

  1. The SARS-CoV-2 main protease as drug target. Ullrich S, Nitsche C. Bioorg Med Chem Lett 30 127377 (2020)
  2. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  3. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Mengist HM, Dilnessa T, Jin T. Front Chem 9 622898 (2021)
  4. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. Hu Q, Xiong Y, Zhu GH, Zhang YN, Zhang YW, Huang P, Ge GB. MedComm (2020) 3 e151 (2022)
  5. Fragment-based covalent ligand discovery. Lu W, Kostic M, Zhang T, Che J, Patricelli MP, Jones LH, Chouchani ET, Gray NS. RSC Chem Biol 2 354-367 (2021)
  6. A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Saied EM, El-Maradny YA, Osman AA, Darwish AMG, Abo Nahas HH, Niedbała G, Piekutowska M, Abdel-Rahman MA, Balbool BA, Abdel-Azeem AM. Pharmaceutics 13 1759 (2021)
  7. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies. Zhang S, Wang L, Cheng G. Mol Ther 30 1869-1884 (2022)
  8. Accelerating antiviral drug discovery: lessons from COVID-19. von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, Tallarico JA, Lee AA. Nat Rev Drug Discov 22 585-603 (2023)
  9. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds. Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. Comput Struct Biotechnol J 20 1306-1344 (2022)
  10. Fragment-to-Lead Medicinal Chemistry Publications in 2020. de Esch IJP, Erlanson DA, Jahnke W, Johnson CN, Walsh L. J Med Chem 65 84-99 (2022)
  11. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  12. A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process. Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, Lima GMA, Rosa HVD, Pereira HD, Zeri ACM, Nascimento AFZ, Freire MCLC, Fearon D, Douangamath A, von Delft F, Oliva G, Godoy AS. J Mol Biol 433 167118 (2021)
  13. Fragment-based drug discovery-the importance of high-quality molecule libraries. Bon M, Bilsland A, Bower J, McAulay K. Mol Oncol 16 3761-3777 (2022)
  14. Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development. Huang F, Han X, Xiao X, Zhou J. Molecules 27 7728 (2022)
  15. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Amin SA, Banerjee S, Gayen S, Jha T. Eur J Med Chem 215 113294 (2021)
  16. High-Throughput Native Mass Spectrometry Screening in Drug Discovery. Gavriilidou AFM, Sokratous K, Yen HY, De Colibus L. Front Mol Biosci 9 837901 (2022)
  17. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Waman VP, Sen N, Varadi M, Daina A, Wodak SJ, Zoete V, Velankar S, Orengo C. Brief Bioinform 22 742-768 (2021)
  18. Impact of structural biologists and the Protein Data Bank on small-molecule drug discovery and development. Burley SK. J Biol Chem 296 100559 (2021)
  19. Discovery of allosteric binding sites by crystallographic fragment screening. Krojer T, Fraser JS, von Delft F. Curr Opin Struct Biol 65 209-216 (2020)
  20. Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. Asada K, Komatsu M, Shimoyama R, Takasawa K, Shinkai N, Sakai A, Bolatkan A, Yamada M, Takahashi S, Machino H, Kobayashi K, Kaneko S, Hamamoto R. J Pers Med 11 886 (2021)
  21. Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease. Sarkar A, Mandal K. Angew Chem Int Ed Engl 60 23492-23494 (2021)
  22. Folding@home: Achievements from over 20 years of citizen science herald the exascale era. Voelz VA, Pande VS, Bowman GR. Biophys J 122 2852-2863 (2023)
  23. The rise of molecular simulations in fragment-based drug design (FBDD): an overview. Bissaro M, Sturlese M, Moro S. Drug Discov Today 25 1693-1701 (2020)
  24. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Singh N, Villoutreix BO. Comput Struct Biotechnol J 19 2537-2548 (2021)
  25. The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2. Jin Z, Wang H, Duan Y, Yang H. Biochem Biophys Res Commun 538 63-71 (2021)
  26. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents. Alzyoud L, Ghattas MA, Atatreh N. Drug Des Devel Ther 16 2463-2478 (2022)
  27. Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. Pozzi C, Vanet A, Francesconi V, Tagliazucchi L, Tassone G, Venturelli A, Spyrakis F, Mazzorana M, Costi MP, Tonelli M. J Med Chem 66 3664-3702 (2023)
  28. Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence. Moreira-Filho JT, Silva AC, Dantas RF, Gomes BF, Souza Neto LR, Brandao-Neto J, Owens RJ, Furnham N, Neves BJ, Silva-Junior FP, Andrade CH. Front Immunol 12 642383 (2021)
  29. Structural biology in the time of COVID-19: perspectives on methods and milestones. Lynch ML, Snell EH, Bowman SEJ. IUCrJ 8 335-341 (2021)
  30. Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. McAulay K, Bilsland A, Bon M. Pharmaceuticals (Basel) 15 1366 (2022)
  31. Science's Response to CoVID-19. Long MJC, Aye Y. ChemMedChem 16 2288-2314 (2021)
  32. A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Littler DR, MacLachlan BJ, Watson GM, Vivian JP, Gully BS. Biochem Soc Trans 48 2625-2641 (2020)
  33. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  34. Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors. Song L, Gao S, Ye B, Yang M, Cheng Y, Kang D, Yi F, Sun JP, Menéndez-Arias L, Neyts J, Liu X, Zhan P. Acta Pharm Sin B 14 87-109 (2024)
  35. On the origins of SARS-CoV-2 main protease inhibitors. Janin YL. RSC Med Chem 15 81-118 (2024)
  36. Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization. Minetti CA, Remeta DP. Life (Basel) 12 1438 (2022)
  37. Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. Zhou Y, Wang H, Yang L, Wang Q. Molecules 27 8257 (2022)
  38. Computational anti-COVID-19 drug design: progress and challenges. Wang J, Zhang Y, Nie W, Luo Y, Deng L. Brief Bioinform 23 bbab484 (2022)
  39. Recent Advances on Targeting Proteases for Antiviral Development. Borges PHO, Ferreira SB, Silva FP. Viruses 16 366 (2024)
  40. The impact of high-resolution structural data on stemming the COVID-19 pandemic. Cox RM, Plemper RK. Curr Opin Virol 49 127-138 (2021)
  41. 3-chymotrypsin-like protease in SARS-CoV-2. Al Adem K, Ferreira JC, Villanueva AJ, Fadl S, El-Sadaany F, Masmoudi I, Gidiya Y, Gurudza T, Cardoso THS, Saksena NK, Rabeh WM. Biosci Rep 44 BSR20231395 (2024)
  42. Fragment-based drug discovery campaigns guided by native mass spectrometry. Sternicki LM, Poulsen SA. RSC Med Chem 15 2270-2285 (2024)
  43. Technologies for Direct Detection of Covalent Protein-Drug Adducts. Mons E, Kim RQ, Mulder MPC. Pharmaceuticals (Basel) 16 547 (2023)

Articles citing this publication (197)